Divi’s Q2 FY27 Profit Jumps 64% as Revenue Hits ₹3,676 Crore
Divi’s Laboratories reported a 63.6% rise in Q2 FY27 consolidated profit to ₹1,127 crore as revenue from operations grew 35.4% to ₹3,676 crore.
Divi’s Laboratories reported a 63.6% rise in Q2 FY27 consolidated profit to ₹1,127 crore as revenue from operations grew 35.4% to ₹3,676 crore.
AstraZeneca Pharma India will launch Datverzo for HR-positive, HER2-negative breast cancer in November 2026 as Q2 FY27 revenue rose 30% to ₹729 crore.
Dimension NXG launches OJAS Forward Deployed Engineering so hospitals can run clinical AI on their own servers ahead of India’s May 2027 DPDP deadline.
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
NHA demonstrated Sandbox 2.0 with agentic AI and Ambient Voice Scribe at its Kolkata ABDM review on 5–6 Nov 2026, speeding HIS partner onboarding.
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
IIT Jodhpur and ICMR-NIHR launched a Collaborative Research Centre on 5 Nov 2026 to build indigenous AIoT diagnostics linked to ABDM for rural Rajasthan.
Symbiotec signs a 10-year take-or-pay CDMO agreement with a European innovator for fermentation-based alternative protein at its Ujjain campus.
Aurobindo Pharma’s Q2 FY27 net profit rose 32.5% to ₹1,124 crore as revenue hit a record ₹10,263 crore on US and Europe growth and 12 USFDA approvals.
Tripura earned NHA recognition for digital health and will make all government hospitals fully paperless from 10 November 2026 under IHMIS.
Union Health Ministry proposes immediate suspension of drug manufacturing licences for NSQ findings on assay, dissolution, impurities or sterility.
Patna has linked 1.13 crore health records under the Ayushman Bharat Digital Mission, the most in Bihar, ahead of Muzaffarpur and Saran districts.
Aarti Drugs’ Q2 FY27 net profit rose 83% to ₹82.8 crore as revenue grew 27% to ₹828.8 crore and the EBITDA margin hit a near six-year high of 16.6%.